Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
DTIL Stock Chart & Stats
$6.14
-$0.10(-2.09%)
At close: 4:00 PM EST
$6.14
-$0.10(-2.09%)
Day’s Range― - ―
52-Week Range$3.61 - $9.14
Previous CloseN/A
Volume55.33K
Average Volume (3M)123.92K
Market Cap
$88.69M
Enterprise Value$13.60M
Total Cash (Recent Filing)$44.87M
Total Debt (Recent Filing)$29.13M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Mar 17, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding13,256,751
10 Day Avg. Volume185,671
30 Day Avg. Volume123,923
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.46
Price to Sales (P/S)0.38
P/FCF Ratio-0.44
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue19.48
Enterprise Value/Gross Profit-20.23
Enterprise Value/Ebitda-0.17
Forecast
1Y Price Target
$45.00Price Target Upside632.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityPrecision Biosciences has a cash runway into the second half of 2027, indicating financial stability and the ability to advance its programs.
Gene Therapy AdvancementsPBGENE-DMD, an in vivo gene editing therapy designed to restore functional near full-length dystrophin and improve long-term muscle function, has shown significant, sustained functional improvement in preclinical models, underscoring PBGENE-DMD's potential as a one-time, disease-modifying treatment for DMD.
Regulatory And Clinical ProgressMultiple clinical and regulatory catalysts underscore positioning toward an inflection point over the next 12 months.
Bears Say
Access And Equity ChallengesDespite scientific progress, it was emphasized that many families—particularly those in rural or resource-limited settings—continue to face delayed diagnosis, fragmented access to specialized centers, and financial barriers that limit participation in clinical trials or access to novel therapies.
Data Collection LimitationsThe efficacy readout is different as liver biopsy is not being conducted in Phase 1 trial.
Treatment Efficacy ConcernsCurrent dose levels in human trials are significantly lower than those that showed over 90% antigen reduction in animal studies, indicating a gap in efficacy.
Precision BioSciences News
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $3.61 and its highest was $9.14 in the past 12 months.
What is Precision BioSciences’s market cap?
Precision BioSciences’s market cap is $88.69M.
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Mar 17, 2026 which is in 128 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Nov 03, 2025. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.5.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -0.6.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 13,256,751 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went down -9.804%.
Which hedge fund is a major shareholder of Precision BioSciences?
Currently, no hedge funds are holding shares in DTIL
Precision BioSciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$45.00 (632.90% Upside)
$45.00 (632.90% Upside)
Hedge Fund Trend
Decreased
By 426.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.91%
12-Months-Change
Fundamentals
Return on Equity
-205.16%
Trailing 12-Months
Asset Growth
-34.30%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
DTIL Stock 12 Month Forecast
Average Price Target
$45.00
▲(632.90% Upside)
Technical Analysis
Bluebird Bio
―
CytomX Therapeutics
―
Adicet Bio
―
ImageneBio
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
3.44% Insiders
5.73% Mutual Funds
0.36% Other Institutional Investors
87.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---